RecruitingNCT05991219

Screening and Secondary Prevention Rheumatic Heart Disease Study

Screening and Secondary Prevention Rheumatic Heart Disease


Sponsor

National Institute of Cardiovascular Diseases, Pakistan

Enrollment

5,000 participants

Start Date

Sep 26, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.


Eligibility

Min Age: 10 YearsMax Age: 30 Years

Inclusion Criteria1

  • Rural communities in Sindh

Exclusion Criteria1

  • Refused to participate in the study

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

National Institute of Cardiovascular Diseases (NICVD)

Karachi, Sindh, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05991219


Related Trials